About OLIGOWIZARD
Supporting researchers in nucleic acid chemistry and oligo therapeutics with computational tools, a reliable knowledgebase, and expert consulting on preclinical development of nucleic acid therapeutics.
Our Team
Phil Becker
Director
Biochemist passionate about targeted delivery of oligo conjugates. Phil explored oligo-conjugate chemistry towards effective delivery beyond hepatocytes for his PhD at ETH Zurich. During his fellowship at Oxford University he studied the RNA structure-function relationship in RNA viruses.
Alyssa Hill
VP Oligo Therapeutics
Expert in design and evaluation of antisense oligonucleotides (ASOs), siRNAs, and conjugates. Group Leader at Oxford University, with extensive experience in oligonucleotide delivery and therapeutic development. Her work spans from viral RNA structures to targeted delivery systems for nucleic acid therapeutics.
Eva-Maria Levasseur
Rare Diseases & Personalised Medicine
Eva-Maria Manz supports the team with her strong background in biology and rare diseases. Her PhD covers gene editing for personalised medicine, as well as mechanistic studies of ASO pharmacodynamics. Eva-Maria serves on the board of directors at the Oligonucleotide Therapeutics Society (OTS)
Tobias Haab
Head of Chemistry
With an MSc in organic chemistry from ETH Zurich, Tobi optimised the synthesis of stereopure phosphorothioate oligos. His PhD work focuses on state-of-the-art backbone modifications including neutral charge modalities.
Advisory Board
Benjamin Dodsworth
Advisor
CSO of PIPRA AG and entrepreneurial life scientist. Ben earned a DPhil from Oxford in cell biology, served as an I2I Fellow at Oxford's Saïd Business School, and brings experience from Roche, Pfizer, and R-Biopharm.